Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder

Why did the Federal Reserve cut interest rates? How did the TikTok deal impact Oracle's comeback? What caused Nvidia's stock to drop in China? Why was Jimmy Kimmel's show pulled off air? How is AI affecting jobs according to Anthropic CEO? What led to Cracker Barrel's sales decline? Why are Starbucks workers suing over dress code?

Regeneron Touts Positive Data From Phase 3 Study In Patients With Ultra-Rare Genetic Disorder

benzinga.com/markets/large-cap/25/09/47720511/regeneron-touts-positive-data-from-phase-3-study-in-patients-with-ultra-rare-genetic-disorder

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported positive results from its Phase 3 OPTIMA trial of garetosmab in adults with fibrodysplasia ossificans progressiva (FOP), meeting the study's primary endpoint.
FOP is a rare genetic disorder in which muscle, tendon, and ligament tissue…

This story appeared on benzinga.com, 2025-09-17 16:29:51.